Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
- PMID: 36145711
- PMCID: PMC9503448
- DOI: 10.3390/pharmaceutics14091964
Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
Abstract
Heart failure (HF) is a progressively deteriorating medical condition that significantly reduces both the patients' life expectancy and quality of life. Even though real progress was made in the past decades in the discovery of novel pharmacological treatments for HF, the prevention of premature deaths has only been marginally alleviated. Despite the availability of a plethora of pharmaceutical approaches, proper management of HF is still challenging. Thus, a myriad of experimental and clinical studies focusing on the discovery of new and provocative underlying mechanisms of HF physiopathology pave the way for the development of novel HF therapeutic approaches. Furthermore, recent technological advances made possible the development of various interventional techniques and device-based approaches for the treatment of HF. Since many of these modern approaches interfere with various well-known pathological mechanisms in HF, they have a real ability to complement and or increase the efficiency of existing medications and thus improve the prognosis and survival rate of HF patients. Their promising and encouraging results reported to date compel the extension of heart failure treatment beyond the classical view. The aim of this review was to summarize modern approaches, new perspectives, and future directions for the treatment of HF.
Keywords: angiotensin receptor–neprilysin inhibitor; autonomic modulation; cardiac myosin activation; heart failure; sodium-glucose co-transporter-2 inhibitors; soluble guanylate cyclase activator.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.Pharmacol Ther. 2022 Oct;238:108185. doi: 10.1016/j.pharmthera.2022.108185. Epub 2022 Apr 9. Pharmacol Ther. 2022. PMID: 35413307 Review.
-
Management of Patients with Heart Failure: Focus on New Pharmaceutical and Device Options.Curr Med Chem. 2020;27(27):4522-4535. doi: 10.2174/0929867326666190523083747. Curr Med Chem. 2020. PMID: 31119996
-
A year in heart failure: an update of recent findings.ESC Heart Fail. 2021 Dec;8(6):4370-4393. doi: 10.1002/ehf2.13760. Epub 2021 Dec 16. ESC Heart Fail. 2021. PMID: 34918477 Free PMC article. Review.
-
Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?Future Cardiol. 2021 May;17(3):497-506. doi: 10.2217/fca-2020-0178. Epub 2021 Feb 22. Future Cardiol. 2021. PMID: 33615880
-
A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects.Diabetes Obes Metab. 2023 Jul;25 Suppl 3:33-47. doi: 10.1111/dom.15085. Epub 2023 May 30. Diabetes Obes Metab. 2023. PMID: 37041663 Review.
Cited by
-
Demographic trends and disparities in mortality related to coexisting heart failure and diabetes mellitus among older adults in the United States between 1999 and 2020: A retrospective population-based cohort study from the CDC WONDER database.Int J Cardiol Cardiovasc Risk Prev. 2024 Aug 24;23:200326. doi: 10.1016/j.ijcrp.2024.200326. eCollection 2024 Dec. Int J Cardiol Cardiovasc Risk Prev. 2024. PMID: 39282605 Free PMC article.
-
Nicotinamide Adenine Dinucleotide Supplementation to Alleviate Heart Failure: A Mitochondrial Dysfunction Perspective.Nutrients. 2025 May 29;17(11):1855. doi: 10.3390/nu17111855. Nutrients. 2025. PMID: 40507126 Free PMC article. Review.
-
Advances in the Insulin-Heart Axis: Current Therapies and Future Directions.Int J Mol Sci. 2024 Sep 22;25(18):10173. doi: 10.3390/ijms251810173. Int J Mol Sci. 2024. PMID: 39337658 Free PMC article. Review.
-
Atherogenic index of plasma: a new indicator for assessing the short-term mortality of patients with acute decompensated heart failure.Front Endocrinol (Lausanne). 2024 Jun 10;15:1393644. doi: 10.3389/fendo.2024.1393644. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38915891 Free PMC article.
-
Cardiovascular inhalation for targeted drug delivery in cardiac disease.Heart Fail Rev. 2025 Sep;30(5):1103-1111. doi: 10.1007/s10741-025-10527-w. Epub 2025 May 23. Heart Fail Rev. 2025. PMID: 40410529 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous